Vor Biopharma (VOR) Jefferies Global Healthcare Conference 2026 summary

Company overview and strategic positioning

• Transitioned from cell therapy to focus on telitacicept, a BAFF/APRIL inhibitor licensed from RemeGen, with global rights and development responsibilities.

• Telitacicept is approved in China for multiple autoimmune diseases and is in late-stage development for myasthenia gravis (gMG) and Sjögren's disease.

• Positioned as the most advanced BAFF/APRIL asset globally, with a robust safety and efficacy database supporting launches.

• Market for gMG biologics is rapidly expanding, projected to double to $10 billion in the near future.

• Company has built a strong medical affairs and advisory network to bridge Chinese and global clinical expertise.

Clinical development and trial progress

• Global phase III trial in gMG is enrolling ahead of schedule, with top-line data expected in the first half of 2027.

• Investigators report strong patient demand and positive tolerability, with requests for extended open-label access.

• Phase III trial design incorporates learnings from Chinese studies, including dose selection and patient stratification.

• Sjögren's global phase III trial began dosing in March, targeting 250 patients with a two-year enrollment and three-year data timeline.

• Site selection for Sjögren's trial prioritizes investigators with extensive ESSDAI/ESSPRI experience to ensure data quality.

Mechanistic and efficacy differentiation

• Dual BAFF/APRIL inhibition targets a broader range of pathogenic antibodies (IgG, IgA, IgM) and offers greater durability than FcRn blockade.

• Chinese data show robust and sustained improvement in gMG, attributed to immune repertoire remodulation.

• Efficacy advantages include depth (MG-ADL delta), breadth (proportion of responders), and durability of response.

• Global trials are powered for clinically meaningful differences, with expectations to maintain efficacy advantages even if effect size is diluted.